David A. Siegel Recursion Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 185,100 shares of RXRX stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
185,100
Previous 31,700
483.91%
Holding current value
$1.39 Million
Previous $312,000
491.35%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RXRX
# of Institutions
259Shares Held
192MCall Options Held
787KPut Options Held
1.52M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl24.6MShares$184 Million1.75% of portfolio
-
Baillie Gifford & CO24.1MShares$181 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA16MShares$120 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.3MShares$92.4 Million0.0% of portfolio
-
Kinnevik Ab (Publ) Stockholm, V710.4MShares$78 Million100.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.35B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...